The antihypertensive effect of cysteine

International Journal of Angiology

Volumn 18, Issue 1, 2009, Pages 7-21

  Vasdev, Sudesh ^a   Singal, Pawan ^b   Gill, Vicki ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Advanced glycation end products; Cysteine; Hypertension; Insulin resistance; Nitric oxide; Oxidative stress

Indexed keywords

3 NITROTYROSINE; ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; CAPTOPRIL; CYSTEINE; DEOXYCORTICOSTERONE ACETATE; ENALAPRILAT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP); HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE (NADPH); METHIONINE; REACTIVE NITROGEN SPECIES; SUPEROXIDE DISMUTASE; TEMPOL;

ANTIHYPERTENSIVE ACTIVITY; BIOAVAILABILITY; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHEMICAL STRUCTURE; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY INTAKE; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; ENERGY RESOURCE; GLUCOSE METABOLISM; GLYCATION; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; KIDNEY FUNCTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STABILITY; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 80053007308     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1278316     Document Type: Review

References (220)

1. World Health Organization. Global strategy on diet, physical activity and health. Chronic disease risk factors. (Version current at May 1, 2009).
2. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7. (Pubitemid 17118813)
3. Reaven GM. Insulin resistance, hyperinsulinemia, and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 1991;90:7S-12S.
4. Sagar S, Kallo IJ, Kaul N, Ganguly NK, Sharma BK. Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992;111:103-8.
5. Kumar KV, Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993;19:59-66. (Pubitemid 23310628)
6. Tandon R, Sinha MK, Garg H, Khanna R, Khanna HD. Oxidative stress in patients with essential hypertension. Natl Med J India 2005;18:297-9. (Pubitemid 43230597)
7. Fortuno A, Olivan S, Beloqui O, et al. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens 2004;22:2169-75. (Pubitemid 39463811)
8. Prabha PS, Das UN, Koratkar R, Sagar PS, Ramesh G. Free radical generation, lipid peroxidation and essential fatty acids in uncontrolled essential hypertension. Prostaglandins Leukot Essent Fatty Acids 1990;41:27-33. (Pubitemid 20284955)
9. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endotheliumdependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468-74. (Pubitemid 23133089)
10. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO III. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995;91:1732-8.
11. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Salvetti A. Endothelial dysfunction in hypertension. J Nephrol 2000;13:205-10. (Pubitemid 30449497)
12. Vasdev S, Gill V. Antioxidants in the treatment of hypertension. Int J Angiol 2005;14:60-73. (Pubitemid 43183956)
13. Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group. N Engl J Med 2001;344:3-10. (Pubitemid 32064838)
14. Rebello T, Hodges RE, Smith JL. Short-term effects of various sugars on antinatriuresis and blood pressure changes in normotensive young men. Am J Clin Nutr 1983;38:84-94. (Pubitemid 13065738)
15. Hodges RE, Rebello T. Carbohydrates and blood pressure. Ann Intern Med 1983;98:838-41. (Pubitemid 13135273)
16. Vasdev S, Gill V, Longerich L, Parai S, Gadag V. Salt-induced hypertension in WKY rats: Prevention by alpha-lipoic acid supplementation. Mol Cell Biochem 2003;254:319-26. (Pubitemid 37483768)
17. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats. Nutr Metab Cardiovasc Dis 2000;10:339-46.
18. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group. N Engl J Med 1997;336:1117-24.
19. Appel LJ, Sacks FM, Carey VJ, et al; OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA 2005;294:2455-64. (Pubitemid 41627923)
20. Stamler J, Caggiula A, Grandits GA, Kjelsberg M, Cutler JA. Relationship to blood pressure of combinations of dietary macronutrients. Findings of the multiple risk factor intervention trial (MRFIT). Circulation 1996;94:2417-23. (Pubitemid 26403567)
21. Stamler J, Elliott P, Kesteloot H, et al. Inverse relation of dietary protein markers with blood pressure. Findings for 10,020 men and women in the INTERSALT study. INTERSALT cooperative research group. INTERnational study of SALT and blood pressure. Circulation 1996;94:1629-34.
22. Ruiz FJ, Salom MG, Ingles AC, Quesada T, Vicente E, Carbonell LF. N-acetyl-L-cysteine potentiates depressor response to captopril and enalaprilat in SHRs. Am J Physiol 1994;267:R767-72. (Pubitemid 24297592)
23. Vasdev S, Mian T, Ford CA, Longerich L, Parai S. Role of endogenous aldehydes in spontaneously hypertensive and disulfiram-induced hypertensive rats. Nutr Metab Cardiovasc Dis 1996;6:130-40. (Pubitemid 126545340)
24. Cabassi A, Dumont EC, Girouard H, et al. Effects of chronic N-acetylcysteine treatment on the actions of peroxynitrite on aortic vascular reactivity in hypertensive rats. J Hypertens 2001;19:1233-44. (Pubitemid 32595279)
25. Girouard H, Chulak C, Wu L, Lejossec M, de Champlain J. N-acetylcysteine improves nitric oxide and alpha-adrenergic pathways in mesenteric beds of spontaneously hypertensive rats. Am J Hypertens 2003;16:577-84. (Pubitemid 36829708)
26. Pechanova O, Zicha J, Kojsova S, Dobesova Z, Jendekova L, Kunes J. Effect of chronic N-acetylcysteine treatment on the development of spontaneous hypertension. Clin Sci (Lond) 2006;110:235-42. (Pubitemid 43241485)
27. Zhang L, Fujii S, Igarashi J, Kosaka H. Effects of thiol antioxidant on reduced nicotinamide adenine dinucleotide phosphate oxidase in hypertensive Dahl salt-sensitive rats. Free Radic Biol Med 2004;37:1813-20. (Pubitemid 39441065)
28. Tian N, Rose RA, Jordan S, Dwyer TM, Hughson MD, Manning RD Jr. N-acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension. J Hypertens 2006;24:2263-70. (Pubitemid 44611036)
29. Kunes J, Dobesova Z, Zicha J. Chronic N-acetylcysteine treatment prevents the development of salt hypertension in immature Dahl rats. J Hypertension Supp 2004;22:153. (Abst)
30. Vasdev S, Ford CA, Longerich L, Gadag V, Wadhawan S. Role of aldehydes in fructose induced hypertension. Mol Cell Biochem 1998;181:1-9. (Pubitemid 28127772)
31. Song D, Hutchings S, Pang CC. Chronic N-acetylcysteine prevents fructose-induced insulin resistance and hypertension in rats. Eur J Pharmacol 2005;508:205-10. (Pubitemid 40169921)
32. Rauchova H, Pechanova O, Kunes J, Vokurkova M, Dobesova Z, Zicha J. Chronic N-acetylcysteine administration prevents development of hypertension in N(omega)-nitro-L-arginine methyl ester-treated rats: The role of reactive oxygen species. Hypertens Res 2005;28:475-82. (Pubitemid 41007463)
33. Zicha J, Dobesova Z, Kunes J. Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats. Hypertens Res 2006;29:1021-7. (Pubitemid 46206589)
34. Ciaccio M, Bivona G, Bellia C. Therapeutical approach to plasma homocysteine and cardiovascular risk reduction. Ther Clin Risk Manag 2008;4:219-24. (Pubitemid 351460946)
35. Robin S, Maupoil V, Groubatch F, Laurant P, Jacqueson A, Berthelot A. Effect of a methionine-supplemented diet on the blood pressure of wistar-kyoto and spontaneously hypertensive rats. Br J Nutr 2003;89:539-48. (Pubitemid 36582125)
36. Mariotti F, Hammiche A, Blouet C, Dare S, Tome D, Huneau JF. Medium-term methionine supplementation increases plasma homocysteine but not ADMA and improves blood pressure control in rats fed a diet rich in protein and adequate in folate and choline. Eur J Nutr 2006;45:383-90. (Pubitemid 44630733)
37. Robin S, Maupoil V, Laurant P, Jacqueson A, Berthelot A. Effect of a methionine-supplemented diet on the blood pressure of Sprague-Dawley and deoxycorticosterone acetate-salt hypertensive rats. Br J Nutr 2004;91:857-65. (Pubitemid 38931449)
38. Suarez C, del Arco C, Lahera V, Ruilope LM. N-acetylcysteine potentiates the antihypertensive effect of angiotensin converting enzyme inhibitors. Am J Hypertens 1995;8:859.
39. Barrios V, Calderon A, Navarro-Cid J, Lahera V, Ruilope LM. N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients. Blood Press 2002;11:235-9.
40. Martina V, Masha A, Gigliardi VR, et al. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care 2008;31:940-4.
41. Pennington JA. Supplementary tables-amino acids. In: Allen A, ed. Bowes & Church's Food Values of Portions Commonly Used, 16th edn. Philadelphia: JB Lippincott Company, 1994:A325-77.
42. Rodwell VW. Proteins: Structure and function. In: Murray RK, Granner DK, Mayes PA, Rodwell VW, eds. Harper's Biochemistry, 24th edn. Stamford: Appleton & Lange, 1996:41-51.
43. Chen PF, Tsai AL, Wu KK. Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity. J Biol Chem 1994;269:25062-6. (Pubitemid 24311775)
44. May JM, Qu Z, Li X. Requirement for GSH in recycling of ascorbic acid in endothelial cells. Biochem Pharmacol 2001;62:873-81. (Pubitemid 32816973)
45. May JM, Qu ZC, Neel DR, Li X. Recycling of vitamin C from its oxidized forms by human endothelial cells. Biochim Biophys Acta 2003;1640:153-61. (Pubitemid 36555701)
46. Ho CT, Chan AC. Regeneration of vitamin E in rat polymorphonuclear leucocytes. FEBS Lett 1992;306:269-72.
47. Thornalley PJ. Modification of the glyoxalase system in disease processes and prospects for therapeutic strategies. Biochem Soc Trans 1993;21:531-4. (Pubitemid 23167962)
48. Schauenstein E, Esterbauer H, Zollner H. Aldehydes in biological systems. In: Lagnado JR, ed. Aldehydes in Biological Systems: Their Natural Occurrence and Biological Activities. London: Pion Limited, 1977:1-7.
49. Jourd'heuil D, Hallen K, Feelisch M, Grisham MB. Dynamic state of S-nitrosothiols in human plasma and whole blood. Free Radic Biol Med 2000;28:409-17. (Pubitemid 30110657)
50. Stamler JS, Simon DI, Osborne JA, et al. S-nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA 1992;89:444-8.
51. Scharfstein JS, Keaney JF Jr, Slivka A, et al. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 1994;94:1432-9. (Pubitemid 24309861)
52. Mathews WR, Kerr SW. Biological activity of S-nitrosothiols: The role of nitric oxide. J Pharmacol Exp Ther 1993;267:1529-37. (Pubitemid 24068731)
53. Tullett JM, Rees DD, Shuker DE, Gescher A. Lack of correlation between the observed stability and pharmacological properties of S-nitroso derivatives of glutathione and cysteine-related peptides.Biochem Pharmacol 2001;62:1239-47. (Pubitemid 33055628)
54. Park JW, Billman GE, Means GE. Transnitrosation as a predominant mechanism in the hypotensive effect of S-nitrosoglutathione. Biochem Mol Biol Int 1993;30:885-91. (Pubitemid 23259025)
55. Stuesse DC, Giraud GD, Vlessis AA, Starr A, Trunkey DD. Hemodynamic effects of S-nitrosocysteine, an intravenous regional vasodilator. J Thorac Cardiovasc Surg 2001;122:371-7.
56. Fajans SS, Floyd JC Jr, Knopf RF, Conn FW. Effect of amino acids and proteins on insulin secretion in man. Recent Prog Horm Res 1967;23:617-62.
57. Lavis VR, Williams RH. Studies of the insulin-like actions of thiols upon isolated fat cells. J Biol Chem 1970;245:23-31.
58. Gazit V, Ben-Abraham R, Vofsi O, Katz Y. L-cysteine increases glucose uptake in mouse soleus muscle and SH-SY5Y cells. Metab Brain Dis 2003;18:221-31. (Pubitemid 37187860)
59. Zaidi NF, Lagenaur CF, Abramson JJ, Pessah I, Salama G. Reactive disulfides trigger Ca2+ release from sarcoplasmic reticulum via an oxidation reaction. J Biol Chem 1989;264:21725-36. (Pubitemid 20028742)
60. Tabet F, Savoia C, Schiffrin EL, Touyz RM. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 2004;44:200-8. (Pubitemid 38982163)
61. Suzuki YJ, Ford GD. Inhibition of Ca(2+)-ATPase of vascular smooth muscle sarcoplasmic reticulum by reactive oxygen intermediates. Am J Physiol 1991;261:H568-74.
62. Ikemoto F, Song G, Tominaga M, Yamamoto K. Oxidation-induced increase in activity of angiotensin converting enzyme in the rat kidney. Biochem Biophys Res Commun 1988;153:1032-7.
63. Lopez BE, Wink DA, Fukuto JM. The inhibition of glyceraldehyde-3- phosphate dehydrogenase by nitroxyl (HNO). Arch Biochem Biophys 2007;465:430-6. (Pubitemid 47362003)
64. Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res2000;86:347-54. (Pubitemid 30108830)
65. Morgan PE, Dean RT, Davies MJ. Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products. Arch Biochem Biophys 2002;403:259-69. (Pubitemid 34800207)
66. Jan CR, Chen CH, Wang SC, Kuo SY. Effect of methylglyoxal on intracellular calcium levels and viability in renal tubular cells. Cell Signal 2005;17:847-55.
67. Palmerini CA, Mazzoni M, Saccardi C, Arienti G. The cytosolic calcium concentration is affected by S-nitrosocysteine in human lymphomonocytes. J Biochem Mol Toxicol 2008;22:35-40. (Pubitemid 351360160)
68. Demirkol O, Adams C, Ercal N. Biologically important thiols in various vegetables and fruits. J Agric Food Chem 2004;52:8151-4. (Pubitemid 40053708)
69. Pechanova O, Zicha J, Paulis L, et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 2007;561:129-36. (Pubitemid 46435853)
70. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 1996;271:C1424-37.
71. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501. (Pubitemid 30165039)
72. Tominaga M, Song GB, Ikemoto F, Yamamoto K. Effect of oxidation on the activity of angiotensin converting enzyme in the rat kidney, heart and brain. Clin Exp Hypertens A 1988;10:1271-8. (Pubitemid 19051365)
73. Janero DR, Hreniuk D, Sharif HM. Hydroperoxide-induced oxidative stress impairs heart muscle cell carbohydrate metabolism. Am J Physiol 1994;266:C179-88. (Pubitemid 24058299)
74. Schulpis KH, Reclos GJ, Parthimos T, Parthimos N, Gavriilidis A, Tsakiris S. L-cysteine supplementation protects the erythrocyte glucose-6-phosphate dehydrogenase activity from reduction induced by forced training. Clin Biochem 2006;39:1002-6. (Pubitemid 44442157)
75. Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003;28:509-14. (Pubitemid 38340416)
76. Suzuki YJ, Ford GD. Redox regulation of signal transduction in cardiac and smooth muscle. J Mol Cell Cardiol 1999;31:345-53. (Pubitemid 29089883)
77. Nakashima I, Takeda K, Kawamoto Y, Okuno Y, Kato M, Suzuki H. Redox control of catalytic activities of membrane-associated protein tyrosine kinases. Arch Biochem Biophys 2005;434:3-10. (Pubitemid 40040464)
78. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol 2005;25:1142-7. (Pubitemid 40776600)
79. Gardner CD, Eguchi S, Reynolds CM, Eguchi K, Frank GD, Motley ED. Hydrogen peroxide inhibits insulin signaling in vascular smooth muscle cells. Exp Biol Med (Maywood) 2003;228:836-42. (Pubitemid 37169269)
80. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111:1201-9. (Pubitemid 36519937)
81. Suzuki YJ, Ford GD. Superoxide stimulates IP3-induced Ca2+ release from vascular smooth muscle sarcoplasmic reticulum. Am J Physiol 1992;262:H114-6.
82. Biswas SK, de Faria JB. Which comes first: Renal inflammation or oxidative stress in spontaneously hypertensive rats? Free Radic Res 2007;41:216-24. (Pubitemid 46992872)
83. Trolliet MR, Rudd MA, Loscalzo J. Oxidative stress and renal dysfunction in salt-sensitive hypertension. Kidney Blood Press Res 2001;24:116-23. (Pubitemid 32642065)
84. Janero DR, Burghardt B. Cardiac membrane vitamin E and malondialdehyde levels in heart muscle of normotensive and spontaneously-hypertensive rats. Lipids 1989;24:33-8. (Pubitemid 19040529)
85. Diniz YS, Rocha KK, Souza GA, et al. Effects of N-acetylcysteine on sucrose-rich diet-induced hyperglycaemia, dyslipidemia and oxidative stress in rats. Eur J Pharmacol 2006;543:151-7. (Pubitemid 44092691)
86. Blouet C, Mariotti F, Azzout-Marniche D, et al. Dietary cysteine alleviates sucrose-induced oxidative stress and insulin resistance. Free Radic Biol Med 2007;42:1089-97. (Pubitemid 46371367)
87. Parik T, Allikmets K, Teesalu R, Zilmer M. Evidence for oxidative stress in essential hypertension: Perspective for antioxidant therapy. J Cardiovasc Risk 1996;3:49-54. (Pubitemid 126424946)
88. Uysal M, Bulur H, Sener D, Oz H. Lipid peroxidation in patients with essential hypertension. Int J Clin Pharmacol Ther Toxicol 1986;24:474-6. (Pubitemid 16014630)
89. Kashyap MK, Yadav V, Sherawat BS, et al. Different antioxidants status, total antioxidant power and free radicals in essential hypertension. Mol Cell Biochem 2005;277:89-99. (Pubitemid 41236190)
90. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989;6:593-7. (Pubitemid 19147809)
91. Kharazmi A, Nielsen H, Schiotz PO. N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Immunopharmacol 1988;10:39-46. (Pubitemid 18038167)
92. Sagrista ML, Garcia AE, Africa De Madariaga M, Mora M. Antioxidant and pro-oxidant effect of the thiolic compounds N-acetyl-L-cysteine and glutathione against free radical-induced lipid peroxidation. Free Radic Res 2002;36:329-40. (Pubitemid 35154078)
93. Zachwieja J, Zaniew M, Bobkowski W, et al. Beneficial in vitro effect of N-acetyl-cysteine on oxidative stress and apoptosis. Pediatr Nephrol 2005;20:725-31. (Pubitemid 40663153)
94. Ferrari R, Ceconi C, Curello S, et al. Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents. Am J Med 1991;91:95S-105S.
95. Xia Z, Guo Z, Nagareddy PR, Yuen V, Yeung E, McNeill JH. Antioxidant N-acetylcysteine restores myocardial Mn-SOD activity and attenuates myocardial dysfunction in diabetic rats. Eur J Pharmacol 2006;544:118-25. (Pubitemid 44148577)
96. Bourraindeloup M, Adamy C, Candiani G, et al. N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. Circulation 2004;110:2003-9. (Pubitemid 39331914)
97. Jensen T, Kharazmi A, Schiotz PO, et al. Effect of oral N-acetylcysteine administration on human blood neutrophil and monocyte function. APMIS 1988;96:62-7. (Pubitemid 18085781)
98. De Mattia G, Bravi MC, Laurenti O, et al. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia 1998;41:1392-6. (Pubitemid 28488770)
99. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511-5. (Pubitemid 24379629)
100. Kahn NN, Acharya K, Bhattacharya S, et al. Nitric oxide: The second messenger of insulin. IUBMB Life 2000;49:441-50. (Pubitemid 30436180)
101. Montagnani M, Ravichandran LV, Chen H, Esposito DL, Quon MJ. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 2002;16:1931-42. (Pubitemid 34828099)
102. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-45. (Pubitemid 30180890)
103. Kamide K, Hori MT, Zhu JH, Barrett JD, Eggena P, Tuck ML. Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 1998;32:482-7. (Pubitemid 28429137)
104. Kamide K, Rakugi H, Nagai M, et al. Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 2004;22:121-7. (Pubitemid 38293539)
105. Tiwari S, Riazi S, Ecelbarger CA. Insulin's impact on renal odium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol 2007;293:F974-84. (Pubitemid 47583930)
106. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
107. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992;231:235-40.
108. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002;19:470-5. (Pubitemid 34639157)
109. Harano Y, Suzuki M, Koyama Y, et al. Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases. J Diabetes Complications 2002;16:19-23. (Pubitemid 34168495)
110. Beatty OL, Harper R, Sheridan B, Atkinson AB, Bell PM. Insulin resistance in offspring of hypertensive parents. BMJ 1993;307:92-6. (Pubitemid 23189568)
111. Hulman S, Falkner B, Freyvogel N. Insulin resistance in the conscious spontaneously hypertensive rat: Euglycemic hyperinsulinemic clamp study. Metabolism 1993;42:14-8. (Pubitemid 23019926)
112. Mondon CE, Reaven GM, Azhar S, Lee CM, Rabkin R. Abnormal insulin metabolism by specific organs from rats with spontaneous hypertension. Am J Physiol 1989;257:E491-8.
113. Lembo G, Iaccarino G, Vecchione C, Rendina V, Trimarco B. Insulin modulation of vascular reactivity is already impaired in prehypertensive spontaneously hypertensive rats. Hypertension 1995;26:290-3.
114. Giner V, Coca A, de la Sierra A. Increased insulin resistance in salt sensitive essential hypertension. J Hum Hypertens 2001;15:481-5. (Pubitemid 32640264)
115. Fuenmayor N, Moreira E, Cubeddu LX. Salt sensitivity is associated with insulin resistance in essential hypertension. Am J Hypertens 1998;11:397-402. (Pubitemid 28231450)
116. Sharma AM, Schorr U, Distler A. Insulin resistance in young salt-sensitive normotensive subjects. Hypertension 1993;21:273-9. (Pubitemid 23065164)
117. Ogihara T, Asano T, Ando K, et al. Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats. Diabetes 2001;50:573-83. (Pubitemid 32195222)
118. Ogihara T, Asano T, Ando K, et al. High-salt diet enhances insulin signaling and induces insulin resistance in dahl salt-sensitive rats. Hypertension 2002;40:83-9. (Pubitemid 34755984)
119. Zecchin HG, Bezerra RM, Carvalheira JB, et al. Insulin signaling pathways in aorta and muscle from two animal models of insulin resistance-the obese middle-aged and the spontaneously hypertensive rats. Diabetologia 2003;46:479-91. (Pubitemid 36577790)
120. Kahn CR, Saad MJ. Alterations in insulin receptor and substrate phosphorylation in hypertensive rats. J Am Soc Nephrol 1992;3:S69-77.
121. Ammon HP, Muller PH, Eggstein M, et al. Increase in glucose consumption by acetylcysteine during hyperglycemic clamp. A study with healthy volunteers. Arzneimittelforschung 1992;42:642-5.
122. Hildebrandt W, Hamann A, Krakowski-Roosen H, et al. Effect of thiol antioxidant on body fat and insulin reactivity. J Mol Med 2004;82:336-44. (Pubitemid 38680291)
123. Fulghesu AM, Ciampelli M, Muzj G, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril 2002;77:1128-35. (Pubitemid 34626318)
124. Padgett CM, Whorton AR. Glutathione redox cycle regulates nitric oxide-mediated glyceraldehyde-3-phosphate dehydrogenase inhibition. Am J Physiol 1997;272:C99-108.
125. Zeng J, Davies MJ. Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol 2005;18:1232-41. (Pubitemid 41170247)
126. Thornalley PJ, Battah S, Ahmed N, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003;375:581-92. (Pubitemid 37433506)
127. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids 2003;25:275-81. (Pubitemid 38041265)
128. Dutta U, Cohenford MA, Dain JA. Nonenzymatic glycation of DNA nucleosides with reducing sugars. Anal Biochem 2005;345:171-80. (Pubitemid 41375948)
129. Park YS, Koh YH, Takahashi M, et al. Identification of the binding site of methylglyoxal on glutathione peroxidase: Methylglyoxal inhibits glutathione peroxidase activity via binding to glutathione binding sites arg 184 and 185. Free Radic Res 2003;37:205-11. (Pubitemid 36124347)
130. Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J, Van Obberghen E. Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 2006;55:1289-99. (Pubitemid 44195367)
131. Jia X, Wu L. Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol Cell Biochem 2007;306:133-9. (Pubitemid 350001825)
132. Jia X, Olson DJ, Ross AR, Wu L. Structural and functional changes in human insulin induced by methylglyoxal. FASEB J 2006;20:1555-7.
133. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003;17:1289-91.
134. Lee HJ, Howell SK, Sanford RJ, Beisswenger PJ. Methylglyoxal can modify GAPDH activity and structure. Ann NY Acad Sci 2005;1043:135-45. (Pubitemid 41123899)
135. Collison KS, Parhar RS, Saleh SS, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002;71:433-44.
136. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003;25:283-92. (Pubitemid 38041266)
137. Dargel R. Lipid peroxidation-a common pathogenetic mechanism? Exp Toxicol Pathol 1992;44:169-81.
138. O'Brien PJ, Siraki AG, Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 2005;35:609-62. (Pubitemid 41693601)
139. Thornalley PJ. The glyoxalase system in health and disease. Mol Aspects Med 1993;14:287-371.
140. Lu C, He JC, Cai W, Liu H, Zhu L, Vlassara H. Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc Natl Acad Sci USA 2004;101:11767-72. (Pubitemid 39099304)
141. Vasdev S, Gill V, Parai S, Gadag V. Dietary lipoic acid supplementation attenuates hypertension in Dahl salt sensitive rats. Mol Cell Biochem 2005;275:135-41. (Pubitemid 41030989)
142. Midaoui AE, Elimadi A, Wu L, Haddad PS, de Champlain J. Lipoic acid prevents hypertension, hyperglycemia, and the increase in heart mitochondrial superoxide production. Am J Hypertens 2003;16:173-9. (Pubitemid 36293060)
143. Wang X, Jia X, Chang T, Desai K, Wu L. Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats. J Hypertens 2008;26:765-72. (Pubitemid 351354925)
144. Wang X, Chang T, Jiang B, Desai K, Wu L. Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: Role of methylglyoxal. Am J Hypertens 2007;20:629-36. (Pubitemid 46777256)
145. Wang X, Desai K, Chang T, Wu L. Vascular methylglyoxal metabolism and the development of hypertension. J Hypertens 2005;23:1565-1573. (Pubitemid 41104829)
146. Wang X, Desai K, Clausen JT, Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 2004;66:2315-21. (Pubitemid 41115295)
147. Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 2002;39:809-14. (Pubitemid 34252881)
148. Wu L. The pro-oxidant role of methylglyoxal in mesenteric artery smooth muscle cells. Can J Physiol Pharmacol 2005;83:63-8. (Pubitemid 40754776)
149. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685-94.
150. Cohen MP, Shea E, Chen S, Shearman CW. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 2003;141:242-9. (Pubitemid 36432924)
151. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997;46:1481-90. (Pubitemid 27369087)
152. Iehara N, Takeoka H, Yamada Y, Kita T, Doi T. Advanced glycation end products modulate transcriptional regulation in mesangial cells. Kidney Int 1996;50:1166-72. (Pubitemid 26342806)
153. Fukami K, Ueda S, Yamagishi S, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66:2137-47. (Pubitemid 41115277)
154. Chang T, Wang R, Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic Biol Med 2005;38:286-93. (Pubitemid 39656138)
155. + exchanger 1 in advanced glycation end products-induced proliferation of vascular smooth muscle cell. Biochem Biophys Res Commun 2008;375:384-9.
156. He R, Qu AJ, Mao JM, Wang X, Sun W. Synergistic proliferation induced by insulin and glycated serum albumin in rat vascular smooth muscle cells. Sheng Li Xue Bao 2007;59:1-7.
157. Vasdev S, Ford CA, Longerich L, Parai S, Gadag V. Aldehyde induced hypertension in rats: Prevention by N-acetylcysteine. Artery 1998;23:10-36. (Pubitemid 30045665)
158. McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. Am J Hypertens 2007;20:242-7. (Pubitemid 46283356)
159. Sugiyama S, Miyata T, Ueda Y, et al. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J Am Soc Nephrol 1998;9:1681-8.
160. Leoncini G, Maresca M, Bonsignore A. The effect of methylglyoxal on the glycolytic enzymes. FEBS Lett 1980;117:17-8.
161. Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2007;76:236-44. (Pubitemid 46400134)
162. Haber CA, Lam TK, Yu Z, et al. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: Possible role of oxidative stress. Am J Physiol Endocrinol Metab 2003;285:E744-53. (Pubitemid 37176425)
163. Taddei S, Ghiadoni L, Virdis A, Versari D, Salvetti A. Mechanisms of endothelial dysfunction: Clinical significance and preventive non-pharmacological therapeutic strategies. Curr Pharm Des 2003;9:2385-402. (Pubitemid 37236360)
164. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222-9. (Pubitemid 28265383)
165. Ibarra M, Meneses A, Ransanz V, Castillo C, Hong E. Changes in endothelium-dependent vascular responses associated with spontaneous hypertension and age in rats. Arch Med Res 1995;26 Spec No:S177-83. (Pubitemid 26044951)
166. Kamata K, Yamashita K. Insulin resistance and impaired endothelium-dependent renal vasodilatation in fructose-fed hypertensive rats. Res Commun Mol Pathol Pharmacol 1999;103:195-210. (Pubitemid 29383634)
167. Manning RD Jr, Hu L, Tan DY, Meng S. Role of abnormal nitric oxide systems in salt-sensitive hypertension. Am J Hypertens 2001;14:68S-73S (Pubitemid 32506699)
168. Scherrer U, Sartori C. Defective nitric oxide synthesis: A link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity. Eur J Endocrinol 2000;142:315-23. (Pubitemid 30230753)
169. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
170. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998;273:25804-8.
171. Ramasamy S, Drummond GR, Ahn J, et al. Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells. Mol Pharmacol 1999;56:116-23. (Pubitemid 29309819)
172. Xia Z, Liu M, Wu Y, et al. N-acetylcysteine attenuates TNF-lphainduced human vascular endothelial cell apoptosis and restores eNOS expression. Eur J Pharmacol 2006;550:134-42. (Pubitemid 44572264)
173. Xia Z, Nagareddy PR, Guo Z, Zhang W, McNeill JH. Antioxidant N-acetylcysteine restores systemic nitric oxide availability and corrects depressions in arterial blood pressure and heart rate in diabetic rats. Free Radic Res 2006;40:175-84. (Pubitemid 43050880)
174. Pieper GM, Siebeneich W. Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction. J Cardiovasc Pharmacol 1998;32:101-5. (Pubitemid 28304701)
175. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 2001;37:117-23. (Pubitemid 32051726)
176. Zembowicz A, Hatchett RJ, Radziszewski W, Gryglewski RJ. Inhibition of endothelial nitric oxide synthase by ebselen. Prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase. J Pharmacol Exp Ther 1993;267:1112-8. (Pubitemid 24068673)
177. Gandley RE, Tyurin VA, Huang W, et al. S-nitrosoalbuminmediated relaxation is enhanced by ascorbate and copper: Effects in pregnancy and preeclampsia plasma. Hypertension 2005;45:21-7. (Pubitemid 40066408)
178. Dicks AP, Williams DL. Generation of nitric oxide from S-nitrosothiols using protein-bound Cu2+ sources. Chem Biol 1996;3:655-9. (Pubitemid 26351774)
179. Nikitovic D, Holmgren A. S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J Biol Chem 1996;271:19180-5. (Pubitemid 26271582)
180. Jensen DE, Belka GK, Du Bois GC. S-nitrosoglutathione is a substrate for rat alcohol dehydrogenase class III isoenzyme. Biochem J 1998;331:659-68. (Pubitemid 28182185)
181. Hoque A, Bates JN, Lewis SJ. In vivo evidence that L-Snitrosocysteine may exert its vasodilator effects by interaction with thiol residues in the vasculature. Eur J Pharmacol 1999;384:169-72. (Pubitemid 30006952)
182. Kowaluk EA, Fung HL. Spontaneous liberation of nitric oxide cannot account for in vitro vascular relaxation by S-nitrosothiols. J Pharmacol Exp Ther 1990;255:1256-64.
183. Ricardo KF, Shishido SM, de Oliveira MG, Krieger MH. Characterization of the hypotensive effect of S-nitroso-Nacetylcysteine in normotensive and hypertensive conscious rats. Nitric Oxide 2002;7:57-66. (Pubitemid 35007261)
184. Keaney JF Jr, Simon DI, Stamler JS, et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 1993;91:1582-9. (Pubitemid 23127360)
185. Lewis SJ, Owen JR, Bates JN. S-nitrosocysteine elicits hemodynamic responses similar to those of the Bezold-Jarisch reflex via activation of stereoselective recognition sites. Eur J Pharmacol 2006;531:254-8. (Pubitemid 43202243)
186. Davisson RL, Travis MD, Bates JN, Lewis SJ. Hemodynamic effects of L-and D-S-nitrosocysteine in the rat. Stereoselective S-nitrosothiol recognition sites. Circ Res 1996;79:256-62. (Pubitemid 26255877)
187. Zhang Y, Hogg N. The mechanism of transmembrane S-nitrosothiol transport. Proc Natl Acad Sci USA 2004;101:7891-6. (Pubitemid 38698024)
188. Afanas'ev IB. Signaling functions of free radicals superoxide and nitric oxide under physiological and pathological conditions. Mol Biotechnol 2007;37:2-4.
189. Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-Snitrosylation. Science 1998;279:234-7. (Pubitemid 28103882)
190. Marshall HE, Stamler JS. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 2001;40:1688-93.
191. Zaman K, Palmer LA, Doctor A, Hunt JF, Gaston B. Concentration-dependent effects of endogenous S-nitrosoglutathione on gene regulation by specificity proteins Sp3 and Sp1. Biochem J 2004;380:67-74. (Pubitemid 38725730)
192. Padgett CM, Whorton AR. S-nitrosoglutathione reversibly inhibits GAPDH by S-nitrosylation. Am J Physiol 1995;269:C739-49.
193. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002;40:872-9. (Pubitemid 35434909)
194. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-84. (Pubitemid 44743495)
195. Tuck ML, Bounoua F, Eslami P, Nyby MD, Eggena P, Corry DB. Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells. J Hypertens 2004;22:1779-85. (Pubitemid 39141971)
196. Luvara G, Pueyo ME, Philippe M, et al. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: Prevention by angiotensin w antagonism. Arterioscler Thromb Vasc Biol 1998;18:1408-16. (Pubitemid 28421878)
197. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/ angiotensin II crosstalk. J Clin Invest 1997;100:2158-69. (Pubitemid 27500137)
198. Wei Y, Sowers JR, Nistala R, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 2006;281:35137-46. (Pubitemid 46036553)
199. Landmesser U, Cai H, Dikalov S, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002;40:511-5.
200. Wolf G, Jablonski K, Schroeder R, Reinking R, Shankland SJ, Stahl RA. Angiotensin II-induced hypertrophy of proximal tubular cells requires p27Kip1. Kidney Int 2003;64:71-81. (Pubitemid 36714159)
201. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8. (Pubitemid 24176909)
202. Boesgaard S, Aldershvile J, Poulsen HE, Christensen S, Dige-Petersen H, Giese J. N-acetylcysteine inhibits angiotensin converting enzyme in vivo. J Pharmacol Exp Ther 1993;265:1239-44. (Pubitemid 23321025)
203. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 2003;30:860-6. (Pubitemid 37506154)
204. Ullian ME, Gelasco AK, Fitzgibbon WR, Beck CN, Morinelli TA. N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells. J Am Soc Nephrol 2005;16:2346-53. (Pubitemid 41725052)
205. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov 2007;6:917-35. (Pubitemid 350042399)
206. Webb GD, Lim LH, Oh VM, et al. Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. J Pharmacol Exp Ther 2008;324:876-82. (Pubitemid 351185840)
207. Ali MY, Ping CY, Mok YY, et al. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphie? Br J Pharmacol 2006;149:625-34. (Pubitemid 44748055)
208. Zhong G, Chen F, Cheng Y, Tang C, Du J. The role of hydrogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. J Hypertens 2003;21:1879-85. (Pubitemid 37290106)
209. Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biophys Res Commun 2004;313:22-7. (Pubitemid 37524019)
210. Chen L, Ingrid S, Ding Y, et al. Imbalance of endogenous homocysteine and hydrogen sulfide metabolic pathway in essential hypertensive children. Chin Med J 2007;120:389-93. (Pubitemid 46488350)
211. Valderrabano F, Gomez-Campdera F, Jones EH. Hypertension as cause of end-stage renal disease: Lessons from international registries. Kidney Int Suppl 1998;68:S60-6. (Pubitemid 28531778)
212. United States Renal Data Systems Annual Report 2006. Atlas of chronic kidney disease and end-stage renal disease in the united states. Am J Kidney Dis 2007;49:S67-84.
213. Martinez-Maldonado M. Hypertension in end-stage renal disease. Kidney Int Suppl 1998;68:S67-72. (Pubitemid 28531779)
214. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: Mechanisms and implications. Am J Nephrol 2006;26:232-44. (Pubitemid 44114394)
215. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl 1998;68:S14-9. (Pubitemid 28531769)
216. Grandi AM, Maresca AM. Blockade of the renin-angiotensinaldosterone system: Effects on hypertensive target organ damage. Cardiovasc Hematol Agents Med Chem 2006;4:219-28. (Pubitemid 44027710)
217. Baumann M, Stehouwer C, Scheijen J, et al. N epsilon-(carboxymethyl) lysine during the early development of hypertension. Ann NY Acad Sci 2008;1126:201-4. (Pubitemid 351589267)
218. Johnson RJ, Gordon KL, Giachelli C, Kurth T, Skelton MM, Cowley AW Jr. Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. J Hypertens 2000;18:1497-505.
219. Shimizu MH, Coimbra TM, de Araujo M, Menezes LF, Seguro AC. N-acetylcysteine attenuates the progression of chronic renal failure. Kidney Int 2005;68:2208-17. (Pubitemid 43117795)
220. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S. N-acetylcysteine ameliorates renal microcirculation: Studies in rats. Kidney Int 2003;63:634-41. (Pubitemid 36126809)